Gri Bio, INC. (GRI) — 8-K Filings

All 8-K filings from Gri Bio, INC.. Browse 37 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (37)

GRI Bio, Inc. Files 8-K for Material Agreement — Dec 12, 2025 Risk: medium
GRI Bio, Inc. filed an 8-K on December 12, 2025, reporting an entry into a material definitive agreement as of December 11, 2025. The filing also includes finan
8-K Filing — Dec 10, 2025
8-K Filing — Dec 8, 2025
8-K Filing — Dec 2, 2025
GRI Bio, Inc. Files 8-K with Regulatory Updates — Aug 20, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on August 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vallon
GRI Bio, Inc. Files 8-K: Director Changes, Officer Appointments, and More — Aug 13, 2025 Risk: medium
GRI Bio, Inc. filed an 8-K on August 13, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of ne
GRI Bio, Inc. Files 8-K — Jul 31, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on July 31, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc., is in
GRI Bio, Inc. Files 8-K — Jun 26, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on June 26, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vallo
GRI Bio, Inc. Files 8-K — May 23, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on May 23, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI
GRI Bio, Inc. Files 8-K — May 5, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on May 5, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI
GRI Bio, Inc. Reports Change in Certifying Accountant — Apr 16, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on April 16, 2025, reporting changes in its certifying accountant as of April 15, 2025. The company, formerly known as Vallon Pharmac
GRI Bio, Inc. Files 8-K: Material Agreement & Other Events — Apr 2, 2025 Risk: medium
GRI Bio, Inc. announced on April 1, 2025, that it entered into a Material Definitive Agreement. The company also reported on other events and filed financial st
GRI Bio Files 8-K on Financials — Mar 17, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on March 17, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
GRI Bio Faces Delisting Concerns — Mar 11, 2025 Risk: high
GRI Bio, Inc. filed an 8-K on March 10, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known as Vall
GRI Bio, Inc. Files 8-K with Corporate Amendments — Feb 19, 2025 Risk: medium
On February 19, 2025, GRI Bio, Inc. filed an 8-K report detailing several key events. The company announced amendments to its articles of incorporation and byla
GRI Bio, Inc. Files 8-K on Security Holder Votes — Feb 11, 2025 Risk: low
GRI Bio, Inc. filed an 8-K on February 11, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate ac
GRI Bio, Inc. Files 8-K — Dec 20, 2024 Risk: low
GRI Bio, Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. an
GRI BIO, Inc. Files 8-K — Oct 24, 2024 Risk: low
GRI BIO, Inc. filed an 8-K on October 24, 2024, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc., is
GRI BIO, Inc. Files 8-K on Material Agreements & Equity Sales — Oct 22, 2024 Risk: medium
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on October 22, 2024, reporting on several events as of October 21, 2024. These include enteri
GRI BIO, Inc. Files 8-K on Security Holder Votes — Sep 6, 2024 Risk: low
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on September 6, 2024, to report on matters submitted to a vote of its security holders. The c
GRI BIO, Inc. Files 8-K on Security Holder Votes — Aug 23, 2024 Risk: low
GRI BIO, Inc. filed an 8-K on August 23, 2024, to report on matters submitted to a vote of its security holders. The company, formerly known as Vallon Pharmaceu
GRI BIO, Inc. Files 8-K — Jul 26, 2024 Risk: low
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on July 26, 2024, to report other events and financial statements. The company, incorporated
GRI BIO, Inc. Files 8-K for Other Events — Jul 19, 2024 Risk: low
GRI BIO, Inc. filed an 8-K on July 19, 2024, to report other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. until
GRI BIO Faces Delisting Concerns — Jul 8, 2024 Risk: high
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on July 8, 2024, reporting a notice of delisting or failure to satisfy continued listing rule
GRI BIO, Inc. Files 8-K for Material Definitive Agreement — Jun 27, 2024 Risk: medium
GRI BIO, Inc. announced on June 26, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Vallon Pharmaceuticals, Inc., is
GRI BIO, Inc. Reports Director/Officer Changes — Jun 18, 2024 Risk: medium
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on June 17, 2024, reporting on the departure of directors, election of new directors, appoint
GRI BIO, Inc. Files 8-K on Security Holder Rights — Jun 14, 2024 Risk: medium
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on June 13, 2024, reporting material modifications to the rights of security holders, amendme
GRI BIO, Inc. Files 8-K on Security Holder Vote Matters — Jun 7, 2024 Risk: low
GRI BIO, Inc. filed an 8-K on June 7, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Vallon Pharmace
GRI BIO Faces Delisting Concerns — May 22, 2024 Risk: high
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on May 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing ru
GRI BIO, Inc. Enters Material Definitive Agreement — May 20, 2024 Risk: medium
GRI BIO, Inc. announced on May 20, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Vallon Pharmaceuticals, Inc., is i
GRI BIO, Inc. Files 8-K on Operations and Financials — May 13, 2024 Risk: low
GRI BIO, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures a
GRI BIO, Inc. Files 8-K on Operations and Financials — Apr 1, 2024 Risk: low
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on April 1, 2024, reporting on its results of operations and financial condition. The filing
GRI BIO Files 8-K on Material Definitive Agreement — Feb 2, 2024
GRI BIO, Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on February 1, 2024, related to an "Entry into a Material Definitive Agreement.
GRI BIO Amends Charter, Modifies Shareholder Rights — Jan 30, 2024
GRI BIO, Inc. filed an 8-K on January 30, 2024, reporting that on January 29, 2024, they made material modifications to the rights of security holders and amend
GRI BIO Confirms Emerging Growth Company Status in 8-K — Jan 19, 2024
GRI BIO, Inc. filed an 8-K on January 19, 2024, to report that it is an "emerging growth company" as defined by the SEC. This status allows the company to take
GRI BIO Files 8-K: Confirms Emerging Growth Status, Updates Contact Info — Jan 16, 2024
GRI BIO, Inc. filed an 8-K on January 16, 2024, primarily to update its corporate information and confirm its status as an emerging growth company. The filing l
GRI BIO Receives Nasdaq Delisting Notice for Bid Price Deficiency — Jan 8, 2024
GRI BIO, Inc. (GRI) announced on January 5, 2024, that it received a delisting notice from The Nasdaq Capital Market because its common stock failed to maintain

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX